Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status:
Completed
Trial end date:
2017-09-14
Target enrollment:
Participant gender:
Summary
The primary objective was to assess the superiority of darbepoetin alfa versus placebo on the
incidence of red blood cell transfusions during the 24-week double-blind treatment period in
anemic patients with low or intermediate-1 risk MDS.